CVRx

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVRx reports stellar Q4 results, eyes growth opportunities in 2023

CVRx's strong performance in 2022, highlighted by revenue growth and operational advancements, sets a positive trajectory for the company. While challenges persist in European market expansion, the focus on key growth areas and strategic initiatives positions CVRx for continued success in 2023.

CVRx reports stellar Q1 performance, eyes label expansions for growth

CVRx's Q1 2023 showcased robust revenue growth, operational progress, and increased guidance for the full year. While challenges like rising expenses and inventory management exist, the company's focus on profitability, label expansions, and market expansion programs position it well for future success.

CVRx excels in Q2 with robust revenue growth and market expansion

CVRx's strong Q2 performance, revenue growth, and strategic initiatives position the company for future success in the heart failure market.
While facing challenges in clinical trial enrollment and regulatory uncertainties, CVRx's focus on market expansion and pricing optimization presents opportunities for sustained growth.
With a clear roadmap for revenue improvement, cash flow optimization, and market penetration, CVRx is poised to capitalize on the growing demand for its therapies.

CVRx reports robust Q3 performance, raises full-year revenue guidance

CVRx delivered a strong performance in Q3 2023, marked by revenue growth and operational advancements.
While facing challenges like net losses and regulatory uncertainties, the company is well-positioned for future growth.
Opportunities lie in market expansion, revenue growth, and maintaining operational efficiencies for sustained success.

CVRx posts robust Q4 earnings, eyes growth amid leadership transition

CVRx reported strong financial performance in Q4 2023, with significant revenue growth and operational achievements.
The company faces challenges in managing expenses, designing new clinical studies, and balancing growth strategies.
Opportunities lie in expanding market opportunities, engaging stakeholders for new programs, and pursuing aggressive growth strategies.
Guidance for 2024 indicates a positive outlook with revenue projections and strategic focus on growth and operational efficiency.

CVRx reports revenue growth in Q1, focuses on therapy adoption

CVRx's Q1 performance showed revenue growth but faced challenges from disruptions and increased expenses.
Strengthening market development efforts and therapy adoption are key focus areas for CVRx.
Opportunities lie in improving awareness, evidence, and access for Barostim therapy.
Navigating challenges like sales turnover and market dynamics will be crucial for CVRx's growth.

CVRx reports strong revenue growth and strategic leadership enhancements

CVRx's Q2 2024 performance showed revenue growth and strategic leadership enhancements.
While challenges like increased expenses and net losses persist, opportunities for revenue growth exist.
The company's focus on market advocacy and product development positions it for future success.

CVRx reports revenue growth and strategic focus amidst rising expenses

CVRx shows revenue growth and positive therapy outcomes but faces challenges in managing expenses. The company's financial position remains stable with a focus on strategic growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVRx, Inc. engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It operates through the United States, Germany, and Other Countries geographical segments. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2001 and is headquartered in Minneapolis, MN.

CVRx is a high risk, and potential high reward cardiovascular IPO. Absolute valuations look reasonable given the opportunity and FDA approved product, but commercial traction has been lagging in recent years.

CVRx: High Risk And High Potential Reward

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, announced today the closing of its initial public offering of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which includes 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses payable by CVRx, of approximately $144.9 million. All of the shares of common stock were offered by CVRx. CVRx's common stock began trading on the Nasdaq Global Select Market on June 30, 2021, under the ticker symbol “CVRX.”

CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

CVRx has filed to raise $100 million in a U.S. IPO of its common stock. The firm is commercializing a neuromodulation device for treating a certain type of heart failure condition.

CVRx Pursues $100 Million U.S. IPO Plan

CVRx, a medical device maker backed by Johnson & Johnson, filed to sell 6.25 million shares at $15 to $17 each.

Medical Device Maker CVRx to Go Public Next Week

News for CVRx Stock (CVRX)